|
|
Vaccine Detail
|
Boostrix |
| Vaccine Information |
- Vaccine Name: Boostrix
- Target Pathogen: Bordetella pertussis
- Target Disease: Whooping Cough
- Product Name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
- Tradename: Boostrix
- Manufacturer: GlaxoSmithKline Biologicals
- Vaccine Ontology ID: VO_0000015
- CDC CVX code: 20, 115
- Type: Toxoid vaccine
- Status: Licensed
- Location Licensed: USA (License #1617)
- Host Species for Licensed Use: Human
- Adjuvant:
- Preparation: Tetanus toxin is produced by growing Clostridium tetani in a modified Latham medium derived from bovine casein. Toxins are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration (FDA: Boostrix).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze.
- Approved Age for Licensed Use: BOOSTRIX is approved for use in individuals 10 through 64 years of age
- Contraindication: A severe allergic reaction after a previous dose of any tetanus toxoid-diphtheria toxoid or pertussis antigen containing vaccine or any component of this vaccine is a contraindication to administration of BOOSTRIX (FDA: Boostrix).
- Description: BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) is a noninfectious, sterile, vaccine for intramuscular administration. It contains tetanus toxoid, diphtheria toxoid, and pertussis antigens (inactivated pertussis toxin [PT] and formaldehyde-treated filamentous hemagglutinin [FHA] and pertactin). The antigens are the same as those in INFANRIX, but BOOSTRIX is formulated with reduced quantities of these antigens (FDA: Boostrix).
|
| Host Response |
|
|
| References |
FDA: Boostrix: FDA: Boostrix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm]
|
|
